SARS-CoV-2 (2019-nCoV) Spike RBD, Recombinant, aa319-541, His-Tag

Katalog-Nummer 497077-20ug

Size : 20ug

Marke : US Biological

Contact local distributor :


Telefonnummer : +1 850 650 7790


497077 SARS-CoV-2 (2019-nCoV) Spike RBD, Recombinant, aa319-541, His-Tag

Clone Type
Polyclonal
Swiss Prot
P0DTC2
Grade
Highly Purified
Accession #
QHD43416.1
Shipping Temp
Blue Ice
Storage Temp
-20°C

An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID19). This virus shares highly homological sequence with SARS-CoV, and causes acute, highly lethal pneumonia coronavirus disease 2019 (COVID-19) with clinical symptoms similar to those reported for SARS-CoV and MERSCoV. The genome of this and other emerging pathogenic human CoVs encodes four major structural proteins [spike (S), envelope (E), membrane (M), and nucleocapsid (N)], approximately 16 nonstructural proteins (nsp1–16), and five to eight accessory proteins. Among them, the S protein plays an essential role in viral attachment, fusion, entry, and transmission. It comprises an N-terminal S1 subunit responsible for virus–receptor binding and a C-terminal S2 subunit responsible for virus–cell membrane fusion. S1 is further divided into an N-terminal domain (NTD) and a receptor-binding domain (RBD). SARS-CoV-2 and SARS-CoV bind angiotensinconverting enzyme 2 (ACE2) while MERS-CoV binds dipeptidyl peptidase 4 (DPP4), as receptors on the host cell|expressing ACE2 (e.g., pneumocytes, enterocytes) or DPP4 (e.g., liver or lung cells including Huh-7, MRC-5, and Calu-3). During infection, CoV first binds the host cell through interaction between its S1-RBD and the cell|membrane receptor, triggering conformational changes in the S2 subunit that result in virus fusion and entry into the target cell. ||Recombinant protein corresponding to aa319-341 from SARS-CoV-2 (2019-nCoV) Spike RBD, fused to His-Tag at C-terminal, expressed in HEK293 cells.||Molecular Weight: |~26.3kD||Biological Activity:|Measured by its binding ability in a functional ELISA with Human ACE-2. ||Amino Acid Sequence:|<DGSM>RVQPTE SIVRFPNITN LCPFGEVFNA TRFASVYAWN RKRISNCVAD YSVLYNSASFSTFKCYGVSP TKLNDLCFTN VYADSFVIRG DEVRQIAPGQ TGKIADYNYK LPDDFTGCVI AWNSNNLDSK VGGNYNYLYR LFRKSNLKPF ERDISTEIYQ AGSTPCNGVE GFNCYFPLQS YGFQPTNGVG YQPYRVVVLS FELLHAPATV CGPKKSTNLV KNKCVNF<HHH HHH>||Storage and Stability: |May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Source: Recombinant, HEK293 cells|Purity: ≥95% by SDS-PAGE. Endotoxin: ≤1EU/1ug (LAL)|Concentration: ~0.5mg/ml (determined by Absorbance at 280nm)|Form: Supplied as a liquid in PBS, pH 7.4, 10% glycerol.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in PBS, pH 7.4, 10% glycerol.
Purity
≥95% (SDS-PAGE). Endotoxin: ≤1EU/1ug (LAL)
References
1. Wu, F. et al. (2020) Nature. 579:265-269, 2. Ortega, J.T. et al. (2020) EXCLI J. 19:410-417, 3. Wanbo T., et al, (2020) Cell. Mol. Immunol. 17:613-620, 4.|Gorbalenya A., et al (2020) Nat. Microbiol. 5:536-544, 5. Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93-116.